Betta Pharmaceuticals (300558.SZ): BPI-572270 capsules approved to conduct clinical trials in Australia

Zhitong Finance APP news, Betta Pharmaceuticals (300558.SZ) announced that the Phase I/II clinical study of BPI-572270 capsules, filed by its wholly-owned subsidiary Hangzhou Jingyao Biotechnology Co., Ltd. (hereinafter referred to as "Jingyao Biotech"), for patients with advanced solid tumors carrying specific RAS mutations, has been reviewed and approved by Australia's Human Research Ethics Committee (HREC), and the clinical trial filing with Australia's Therapeutic Goods Administration (TGA) has been completed. This is the company's first new drug approved for clinical trials in Australia.